Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 7
2005 2
2008 3
2010 2
2011 3
2013 2
2014 2
2015 1
2016 3
2017 10
2018 5
2019 9
2020 17
2021 16
2022 16
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
LDL cholesterol and atherosclerosis: The evidence.
Guijarro C, Cosín-Sales J. Guijarro C, et al. Among authors: cosin sales j. Clin Investig Arterioscler. 2021 May;33 Suppl 1:25-32. doi: 10.1016/j.arteri.2020.12.004. Clin Investig Arterioscler. 2021. PMID: 33966809 Free article. English, Spanish.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Role of rivaroxaban in the prevention of atherosclerotic events.
Sanmartín M, Bellmunt S, Cosín-Sales J, García-Moll X, Riera-Mestre A, Almendro-Delia M, Hernández JL, Lozano F, Mazón P, Suarez Fernández C. Sanmartín M, et al. Among authors: cosin sales j. Expert Rev Clin Pharmacol. 2019 Aug;12(8):771-780. doi: 10.1080/17512433.2019.1637732. Epub 2019 Jul 9. Expert Rev Clin Pharmacol. 2019. PMID: 31269825 Review.
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias.
SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe; Grupo de Trabajo de la SEC para la guía ESC 2019 sobre el tratamiento de las dislipemias; Revisores expertos para la ESC 2019 sobre el tratamiento de las dislipemias; Comité de Guías de la SEC. SEC Working Group for the 2019 ESC EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe, et al. Rev Esp Cardiol (Engl Ed). 2020 May;73(5):348-353. doi: 10.1016/j.rec.2019.11.019. Epub 2020 Mar 21. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32205101 English, Spanish. No abstract available.
Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Zatarain-Nicolás E, Martín P, Márquez Rodas I, Virizuela J, Martín García A, Mitroi C, Cosín Sales J, Barrios V, Sánchez-Cabo F, Ibañez B, de Castro Carpeño J, López Fernández T. Zatarain-Nicolás E, et al. Among authors: cosin sales j. Clin Transl Oncol. 2023 Nov;25(11):3073-3085. doi: 10.1007/s12094-023-03217-2. Epub 2023 May 25. Clin Transl Oncol. 2023. PMID: 37227656 Review.
97 results